Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.58 |
| ▸ | LCK | P06239 | 5/20 | 0.58 |
| ▸ | SRC | P12931 | 4/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.58 |
| ▸ | ADK | P55263 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 5/20 | 0.50 |
| ▸ | TEK | Q02763 | 4/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
| ▸ | PRKDC | P78527 | 2/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732639 | 0.88 | RET (0.58) | RETLCKSRCPDPK1KDR | |
| SCHEMBL6223045 | 0.83 | PDGFRB (0.57) | RETLCKSRCPDPK1KDR | |
| SCHEMBL7700357 | 0.83 | SRC (0.47) | RETLCKSRCPDPK1ADK | |
| SCHEMBL1942060 | 0.82 | PDGFRB (0.66) | RETLCKSRCPDPK1KDR | |
| SCHEMBL18100426 | 0.80 | ADK (0.55) | RETLCKSRCPDPK1ADK | |
| SCHEMBL6220421 | 0.80 | PDGFRB (0.54) | RETLCKSRCPDPK1KDR | |
| SCHEMBL4079287 | 0.79 | PDPK1 (0.55) | RETLCKSRCPDPK1KDR | |
| SCHEMBL24258000 | 0.78 | PIK3CD (0.51) | RETLCKSRCPDPK1KDR | |
| SCHEMBL25750400 | 0.78 | TYK2 (0.40) | RETLCKSRCPDPK1KDR | |
| SCHEMBL4090458 | 0.78 | PDPK1 (0.59) | RETLCKSRCPDPK1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201236-A1 | SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | Janssen Pharmaceuticals, Inc. | 2022-02-03 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2015077360-A2 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033406-A1 | CYCLOPENTYL NUCLEOSIDE ANALOGS AS ANTI-VIRALS | PNP, TYMP, HAVCR2 | RET 4850/4885LCK 4397/4885SRC 4752/4885 |
| US-20160280729-A1 | CYCLOPENTANE AND CYCLOPENTENE NUCLEOSIDE ANALOGS FOR THE TREATMENT OF HCV | ZC3HAV1, HAVCR2, NSUN2 | RET 4124/4885LCK 2939/4885SRC 2945/4885 |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | RET 2926/4885LCK 3724/4885SRC 4638/4885 |
| US-20230201236-A1 | SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E | HAVCR2, NME2, SLC10A1 | RET 3382/4885LCK 3757/4885SRC 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.